Atrium and paroxetine-related severe hepatitis

Journal of Clinical Gastroenterology

Volumn 28, Issue 1, 1999, Pages 52-55

  Cadranel, Jean François ^a   Di Martino, Vincent ^a   Cazier, Alain ^a   Pras, Véronique ^b   Bachmeyer, Claude ^a   Olympio, Paul ^a   Gonzenbach, Alain ^a   Mofredj, Ali ^a   Coutarel, Pierre ^a   Devergie, Bruno ^a   Biour, Michel ^b  

^a CENTRE HOSPITALIER LAENNEC   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Atrium; Hepatotoxicity; Microsomes; Paroxetine; Severe hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PAROXETINE; PROTHROMBIN; TETRABAMATE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CASE REPORT; DEPRESSION; DISEASE SEVERITY; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; INSOMNIA; JAUNDICE; LIVER BIOPSY; LIVER TOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME;

ADULT; ANTI-ANXIETY AGENTS; BARBITURATES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER; PAROXETINE; PHENOBARBITAL; SEROTONIN UPTAKE INHIBITORS;

EID: 0032897596     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199901000-00014     Document Type: Article

References (21)

1. Horsmans Y, Larrey D, Pessayre D, Degott C, Benhamou JP. Hépatites au cours de l'administration d' Atrium®. Observations de quatre cas. Gastroenterol Clin Biol 1991;15:648-652.
2. Pariente EA, Mineur D. Hépatites d'allure auto-immune à l' Atrium®. Gastroenterol Clin Biol 1992;16:485-486.
3. Cayla JM, Fandi L, Arnould P, Degott C, Gouffier E. Hépatite due à l' Atrium®. Presse Med 1995;24:1665.
4. Schneider S, Charles F, Chichmanian RM, Montoya ML, Rampai P. Hépatite aiguë associée à une stéatose microvesiculaire imputable à l' Atrium®. Gastroenterol Clin Biol 1995;19:1064-1065.
5. Brocheriou I, Zafrani ES, Mavier P. Hépatite aiguë sévère imputable à l' Atrium®. Gastroenterol Clin Biol 1993;17:305-306.
6. Binder D, Salomon F, Flury R, Jost R. Acute liver failure after tetrabamate [abstract]. Schweiz Med Wochenschr 1993;123(Suppl 50):117.
7. Biour M, Poupon R, Grangé JD, et al. Hépatotoxicité des médicaments. Mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol Clin Biol 1996;20:744-779.
8. Danan G, Benichou C, Bégaud B, et al. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11:272-276.
9. Stricker BHC, Biour M, Wilson JMP. Drug-Induced Hepatic Injury. A Comprehensive Survey of the Literature on Adverse Drug Reactions up to January 1992. Amsterdam: Elsevier, 1992: 71-524.
10. Cadranel JF, Buffet C, Bismuth E, et al. Acute cholestatic hepatitis associated with Noctran® use: a case report. Eur J Gastroenterol 1992;4:943-945.
11. Larrey D, Erlinger S. Drug-induced cholestasis. Baillières Clin Gastroenterol 1988;2:423-452.
12. Mars F, Dumas de La Roque G, Goissen P. Hépatite aiguë lors du traitement par la fluoxétine. Gastroenterol Clin Biol 1991;15:270-271.
13. Bobichon R, Bernard G, Mion F. Atteinte hépatique aiguë lors du traitement par la fluoxétine. Gastroenterol Clin Biol 1993;17:406-407.
14. Castiella A, Arenas JI. Fluoxetine hepatotoxicity. Am J Gastroenterol 1994;89:458-459.
15. Friendberg F, Rothstein KD. Hepatitis secondary to fluoxetine treatment. Am J Psychiatry 1996;153:580.
16. Helmchen C, Boerner RJ, Meyendorf R, Hegerl U. Reversible hepatotoxicity of paroxetine in a patient with major depression. Pharmacopsychiatry 1996;29:223-226.
17. Benbow SJ, Gill G. Paroxetine and hepatotoxicity. Br Med J 1997;314:1387.
18. Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible interaction between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium®, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol 1994;21:1075-1079.
19. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996;11(Suppl):31-61.
20. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995;40:481-485.
21. Vial T, Gaudin JL, Cote C, et al. Hépatotoxicité de l' Atrium®: risque propre ou potentialisation de l' hépatotoxicité des antide-presseurs? 15e journées française de pharmacovigilance, Saint Etienne, 1993, abstract P60.